Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2022-06-24 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Communication to shareholders as per Reg 30
Regulatory Filings
2022-06-24 English
Book Closure
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for images and no textual content or substantive information. The true document length is only 168 characters, which is extremely short and contains no report or announcement details. There is no indication of any report, announcement, or filing type. Given the lack of content, the document cannot be classified as any specific report or announcement type and defaults to Regulatory Filings (RNS) as a fallback category.
2022-06-22 English
Communication to shareholders as per Reg 30
Regulatory Filings
2022-06-20 English
Communication to shareholders as per Reg 30
Regulatory Filings Classification · 100% confidence The document text is extremely short (69 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, no report content, no announcements, or any other information to classify as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal or placeholder content defaults to Regulatory Filings (RNS) as a fallback category.
2022-06-18 English
Communication to shareholders as per Reg 30
Regulatory Filings
2022-06-14 English
Reply to Clarification Sought- Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India regarding a clarification on the quick financial results submitted for the year ended March 31, 2022. It discusses the signing and submission of financial results but does not contain the financial results themselves or detailed financial data. The document is short (1303 characters) and serves as a clarification or regulatory communication rather than a full financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such communications that do not contain substantive financial data or full reports.
2022-06-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.